Association analysis of 9,560 prostate cancer cases from the International Consortium of Prostate Cancer Genetics confirms the role of reported prostate cancer associated SNPs for familial disease
详细信息 查看全文
- 作者：Craig C. Teerlink (1)
Stephen N. Thibodeau (3) (4)
Shannon K. McDonnell (3) (5)
Daniel J. Schaid (3) (5)
Antje Rinckleb (6) (7) (8)
Christiane Maier (6) (7) (8)
Walther Vogel (6) (7)
Geraldine Cancel-Tassin (9)
Christophe Egrot (9)
Olivier Cussenot (9)
William D. Foulkes (10) (11)
Graham G. Giles (10) (12) (13)
John L. Hopper (10) (13)
Gianluca Severi (10) (12) (13)
Ros Eeles (10) (14)
Douglas Easton (10) (15)
Zsofia Kote-Jarai (10) (14)
Michelle Guy (10) (14)
Kathleen A. Cooney (16) (17) (18)
Anna M. Ray (16) (17) (18)
Kimberly A. Zuhlke (16) (17) (18)
Ethan M. Lange (16) (19) (20)
Liesel M. FitzGerald (21) (22)
Janet L. Stanford (21) (22)
Elaine A. Ostrander (21) (23)
Kathleen E. Wiley (24)
Sarah D. Isaacs (24)
Patrick C. Walsh (24)
William B. Isaacs (24)
Tiina Wahlfors (25) (26) (27)
Teuvo Tammela (25) (28)
Johanna Schleutker (25) (29)
Fredrik Wiklund (30) (31)
Henrik Gr?nberg (30) (31)
Monica Emanuelsson (30) (32)
John Carpten (33)
Joan Bailey-Wilson (34)
Alice S. Whittemore (35) (36)
Ingrid Oakley-Girvan (35) (37) (38)
Chih-Lin Hsieh (35) (39) (40)
William J. Catalona (41)
S. Lilly Zheng (41)
Guangfu Jin (42)
Lingyi Lu (42)
Jianfeng Xu (42)
Nicola J. Camp (1)
Lisa A. Cannon-Albright (1) (2) - 刊名：Human Genetics
- 出版年：2014
- 出版时间：March 2014
- 年：2014
- 卷：133
- 期：3
- 页码：347-356
- 全文大小：439 KB
- 作者单位：Craig C. Teerlink (1)
Stephen N. Thibodeau (3) (4)
Shannon K. McDonnell (3) (5)
Daniel J. Schaid (3) (5)
Antje Rinckleb (6) (7) (8)
Christiane Maier (6) (7) (8)
Walther Vogel (6) (7)
Geraldine Cancel-Tassin (9)
Christophe Egrot (9)
Olivier Cussenot (9)
William D. Foulkes (10) (11)
Graham G. Giles (10) (12) (13)
John L. Hopper (10) (13)
Gianluca Severi (10) (12) (13)
Ros Eeles (10) (14)
Douglas Easton (10) (15)
Zsofia Kote-Jarai (10) (14)
Michelle Guy (10) (14)
Kathleen A. Cooney (16) (17) (18)
Anna M. Ray (16) (17) (18)
Kimberly A. Zuhlke (16) (17) (18)
Ethan M. Lange (16) (19) (20)
Liesel M. FitzGerald (21) (22)
Janet L. Stanford (21) (22)
Elaine A. Ostrander (21) (23)
Kathleen E. Wiley (24)
Sarah D. Isaacs (24)
Patrick C. Walsh (24)
William B. Isaacs (24)
Tiina Wahlfors (25) (26) (27)
Teuvo Tammela (25) (28)
Johanna Schleutker (25) (29)
Fredrik Wiklund (30) (31)
Henrik Gr?nberg (30) (31)
Monica Emanuelsson (30) (32)
John Carpten (33)
Joan Bailey-Wilson (34)
Alice S. Whittemore (35) (36)
Ingrid Oakley-Girvan (35) (37) (38)
Chih-Lin Hsieh (35) (39) (40)
William J. Catalona (41)
S. Lilly Zheng (41)
Guangfu Jin (42)
Lingyi Lu (42)
Jianfeng Xu (42)
Nicola J. Camp (1)
Lisa A. Cannon-Albright (1) (2)
1. Division of Genetic Epidemiology, Department of Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA
3. Mayo Clinic ICPCG Group, Rochester, MN, USA
4. Department of Lab Medicine and Pathology, Mayo Clinic, Rochester, MN, 55905, USA
5. Department of Health Sciences Research, Mayo Clinic, Rochester, MN, 55905, USA
6. University of Ulm ICPCG Group, Ulm, Germany
7. Department of Urology, University of Ulm, Ulm, Germany
8. Institute for Human Genetics, University of Ulm, Ulm, Germany
9. CeRePP ICPCG Group, Hopital Tenon, Assistance Publique-Hopitaux de Paris, 75020, Paris, France
10. ACTANE Consortium ICPCG Group, Surrey, UK
11. Program in Cancer Genetics, McGill University, Montreal, QC, H3T 1E2, Canada
12. Cancer Epidemiology Centre, Cancer Council Victoria, Carlton, VIC, 3053, Australia
13. Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, The University of Melbourne, Melbourne, VIC, 3010, Australia
14. The Institute of Cancer Research, Sutton, Surrey, SM2 5NG, UK
15. Strangeways Laboratory, Worts Causeway, Cambridge, CB1 8RN, UK
16. University of Michigan ICPCG Group, Ann Arbor, MI, USA
17. Department of Urology, University of Michigan Medical School, Ann Arbor, MI, 48109, USA
18. Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, 48109, USA
19. Department of Genetics, University of North Carolina, Chapel Hill, NC, 27599, USA
20. Department of Biostatistics, University of North Carolina, Chapel Hill, NC, 27599, USA
21. FHCRC/NHGRI ICPCG Group, Seattle, WA, USA
22. Division of Public Health Sciences, Fred Hutchinson Cancer Research Center (FHCRC), Seattle, WA, 98195, USA
23. Cancer Genetics Branch, National Human Genome Research Institute (NHGRI), National Institutes of Health (NIH), Bethesda, MD, 20892, USA
24. Department of Urology, Johns Hopkins University ICPCG Group, Johns Hopkins Medical Institutions, Baltimore, MD, 21287, USA
25. University of Tampere ICPCG Group, Tampere, Finland
26. Institute of Biomedical Technology, University of Tampere, BioMediTech, Tampere, 33520, Finland
27. Centre for Laboratory Medicine, Tampere University Hospital, Tampere, 33520, Finland
28. Department of Urology, University of Tampere and Tampere University Hospital, Tampere, 33520, Finland
29. Department of Medical Biochemistry and Genetics, University of Turku, Turku, 20520, Finland
30. University of Ume? ICPCG Group, Ume?, Sweden
31. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
32. Oncologic Centre, Ume? University, 90187, Ume?, Sweden
33. Integrated Cancer Genomics Division, TGen, Phoenix, AZ, 85004, USA
34. Inherited Disease Research Branch, National Human Genome Research Institute (NHGRI), National Institutes of Health (NIH), Bethesda, MD, 20892, USA
35. Stanford University ICPCG Group, Palo Alto, CA, USA
36. Department of Health Research and Policy, Stanford School of Medicine, Stanford, CA, 94305, USA
37. Cancer Prevention Institute of California, 2201 Walnut Ave Suite 300, Fremont, CA, 94538, USA
38. Stanford Cancer Institute and Department of Health Research and Policy, Stanford School of Medicine, Palo Alto, CA, USA
39. Department of Urology, University of Southern California, Los Angeles, CA, 90089, USA
40. Department of Biochemistry and Molecular Biology, University of Southern California, Los Angeles, CA, 90089, USA
41. Northwestern University ICPCG Group, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA
42. Data Coordinating Center for the ICPCG and Center for Human Genomics, Wake Forest University School of Medicine, Winston-Salem, NC, 27157, USA
2. George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, UT, USA - ISSN：1432-1203
文摘
Previous GWAS studies have reported significant associations between various common SNPs and prostate cancer risk using cases unselected for family history. How these variants influence risk in familial prostate cancer is not well studied. Here, we analyzed 25 previously reported SNPs across 14 loci from prior prostate cancer GWAS. The International Consortium for Prostate Cancer Genetics (ICPCG) previously validated some of these using a family-based association method (FBAT). However, this approach suffered reduced power due to the conditional statistics implemented in FBAT. Here, we use a case–control design with an empirical analysis strategy to analyze the ICPCG resource for association between these 25 SNPs and familial prostate cancer risk. Fourteen sites contributed 12,506 samples (9,560 prostate cancer cases, 3,368 with aggressive disease, and 2,946 controls from 2,283 pedigrees). We performed association analysis with Genie software which accounts for relationships. We analyzed all familial prostate cancer cases and the subset of aggressive cases. For the familial prostate cancer phenotype, 20 of the 25 SNPs were at least nominally associated with prostate cancer and 16 remained significant after multiple testing correction (p?≤?E ?) occurring on chromosomal bands 6q25, 7p15, 8q24, 10q11, 11q13, 17q12, 17q24, and Xp11. For aggressive disease, 16 of the SNPs had at least nominal evidence and 8 were statistically significant including 2p15. The results indicate that the majority of common, low-risk alleles identified in GWAS studies for all prostate cancer also contribute risk for familial prostate cancer, and that some may contribute risk to aggressive disease.